A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2013
At a glance
- Drugs AEG 40826 (Primary)
- Indications Lymphoid leukaemia
- Focus Adverse reactions
- 09 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Nov 2009 New trial record